Intracranial Metastatic Disease: Present Challenges, Future Opportunities

Area of Science:

• Oncology
• Neurology
• Cancer Metastasis Research

Background:

• Intracranial metastatic disease (IMD) significantly impacts cancer patient survival and quality of life.
• Historical understanding of IMD epidemiology and pathogenesis has evolved, informing treatment strategies.
• Biomolecular characteristics and prognostic factors are key to developing surveillance and treatment algorithms.

Purpose of the Study:

• To review current treatment principles for patients diagnosed with intracranial metastatic disease.
• To explore the emerging role of targeted therapy and immunotherapy in managing brain metastases.
• To discuss future research directions in the field of IMD.

Main Methods:

• Review of current literature on intracranial metastatic disease management.
• Analysis of advances in surgical resection, radiation therapy, and systemic treatments.
• Examination of novel diagnostic tools, including advanced imaging and serological assays.

Main Results:

• Treatment of IMD has expanded beyond traditional methods to include monoclonal antibodies and small molecule inhibitors.
• Targeted therapies and immunotherapies show promise in select primary cancers with brain metastases.
• Enhanced imaging sensitivity and new serological assays are improving IMD diagnosis.

Conclusions:

• Current IMD treatment integrates multimodal approaches, including systemic therapies.
• Targeted and immune-based strategies represent a significant advancement in managing brain metastases.
• Continued research is crucial for further optimizing IMD patient outcomes.